American Innovation and R&D Competitiveness Act of 2025

Bill Number: H.R. 1990
Origin Chamber: House
Congress: 119th Congress, Session 1
Policy Area: Taxation
Status: Introduced
Latest Action: 2025-03-10: Referred to the House Committee on Ways and Means.
Last Updated: 2025-12-29T16:08:52Z

AI-Generated Summary

Purpose of the Legislation

The American Innovation and R&D Competitiveness Act of 2025 aims to encourage research and development (R&D) activities by restoring tax benefits for businesses. Specifically, it allows companies to immediately deduct certain R&D expenses from their taxable income, rather than spreading the deductions over several years, to boost innovation and U.S. economic competitiveness.

Key Provisions

Immediate Deduction Option: Businesses can choose to treat R&D expenditures (costs related to developing new or improved products, processes, or techniques) as fully deductible business expenses in the year they are paid or incurred, without adding them to the capital account (which tracks long-term asset costs).
Amortization Alternative: If not immediately deducted, taxpayers can elect to amortize (spread out) these expenses over at least 60 months, starting when benefits from the R&D are realized.
Adoption and Consistency Rules: Taxpayers can adopt the immediate deduction method without IRS approval for their first year of such expenses or with approval later. Once chosen, the method must be used consistently unless the IRS approves a change.
Exclusions: The rules do not apply to costs for acquiring or improving land, depreciable property (assets that lose value over time and qualify for depreciation deductions), depletable resources (like minerals or oil), or mineral exploration. Only reasonable R&D expenditures qualify.
Conforming Changes: Updates related tax code sections, such as adjusting how R&D credits under Section 41 interact with deductions (e.g., reducing deductions by the credit amount or allowing an election for a reduced credit to preserve full deductions).
Effective Date: Applies to tax years beginning after December 31, 2021, allowing retroactive relief.

Significant Changes to Existing Law

This bill reverses changes made by the 2017 Tax Cuts and Jobs Act, which required R&D expenses to be capitalized and amortized over five years (or 15 years for foreign-based R&D) starting in 2022, eliminating immediate full deductions. It restores the pre-2022 treatment, giving businesses more flexibility in how they account for R&D costs and potentially simplifying tax planning.

Potential Impacts

On Government Agencies: The Internal Revenue Service (IRS) may see increased administrative workload for processing elections, approvals for method changes, and audits of R&D claims, but it could also reduce disputes over capitalization rules.
On Citizens and Businesses: U.S. companies, particularly in innovation-heavy sectors, could lower their tax bills, freeing up capital for more R&D investment, job creation, and economic growth. Individual taxpayers might indirectly benefit from a stronger economy, though the changes primarily affect corporate taxes.
On International Relations: By making U.S. tax treatment of R&D more favorable, the law could enhance American competitiveness against countries with generous R&D incentives (e.g., in Europe or Asia), potentially attracting foreign investment and reducing offshoring of research activities.

Main Stakeholders Affected

Businesses and Corporations: Especially those in technology, pharmaceuticals, manufacturing, and software industries that incur significant R&D costs; they gain direct tax savings and incentives to invest more in innovation.
Taxpayers and Investors: Companies' reduced tax liabilities could lead to higher profits, benefiting shareholders and employees through wages or reinvestments.
Government (IRS and Treasury): Responsible for implementing and enforcing the updated rules, including regulations for elections and approvals.
Small Businesses and Startups: May particularly benefit from easier access to immediate deductions, helping them compete without the burden of delayed tax relief.

Notable Legal, Constitutional, or Political Implications

Legal Implications: The bill integrates seamlessly with the existing Internal Revenue Code, avoiding conflicts with other tax provisions like depreciation (Section 167) or depletion (Section 611). It requires IRS regulations for implementation, which could lead to future guidance or challenges in court over what qualifies as "reasonable" R&D.
Constitutional Implications: None significant; as a tax policy adjustment, it falls under Congress's broad authority to levy and regulate taxes under Article I of the U.S. Constitution.
Political Implications: Bipartisan support (over 50 cosponsors from both parties) signals broad agreement on promoting R&D as a non-partisan priority. If enacted, it could influence future tax reform debates, emphasizing incentives for domestic innovation amid global competition, but it may face opposition over potential revenue losses to the federal budget (estimated in billions annually).

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Estes, Ron [R-KS-4]

Cosponsors (81)

Rep. Larson, John B. [D-CT-1], Rep. Buchanan, Vern [R-FL-16], Rep. DelBene, Suzan K. [D-WA-1], Rep. Smith, Adrian [R-NE-3], Rep. Sewell, Terri A. [D-AL-7], Rep. Kelly, Mike [R-PA-16], Rep. Beyer, Donald S. [D-VA-8], Rep. Schweikert, David [R-AZ-1], Rep. Panetta, Jimmy [D-CA-19], Rep. LaHood, Darin [R-IL-16], Rep. Horsford, Steven [D-NV-4], Rep. Arrington, Jodey C. [R-TX-19], Rep. Brownley, Julia [D-CA-26], Rep. Smucker, Lloyd [R-PA-11], Rep. Khanna, Ro [D-CA-17], Rep. Hern, Kevin [R-OK-1], Rep. Bonamici, Suzanne [D-OR-1], Rep. Miller, Carol D. [R-WV-1], Rep. Titus, Dina [D-NV-1], Rep. Murphy, Gregory F. [R-NC-3], Rep. Houlahan, Chrissy [D-PA-6], Rep. Kustoff, David [R-TN-8], Rep. Cleaver, Emanuel [D-MO-5], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Carbajal, Salud O. [D-CA-24], Rep. Steube, W. Gregory [R-FL-17], Rep. Foushee, Valerie P. [D-NC-4], Rep. Tenney, Claudia [R-NY-24], Rep. Scholten, Hillary J. [D-MI-3], Rep. Fischbach, Michelle [R-MN-7], Rep. Davids, Sharice [D-KS-3], Rep. Moore, Blake D. [R-UT-1], Rep. Craig, Angie [D-MN-2], Rep. Van Duyne, Beth [R-TX-24], Rep. Morelle, Joseph D. [D-NY-25], Rep. Feenstra, Randy [R-IA-4], Rep. Davis, Donald G. [D-NC-1], Rep. Malliotakis, Nicole [R-NY-11], Rep. Harder, Josh [D-CA-9], Rep. Carey, Mike [R-OH-15], Rep. Neguse, Joe [D-CO-2], Rep. Yakym, Rudy [R-IN-2], Rep. Auchincloss, Jake [D-MA-4], Rep. Miller, Max L. [R-OH-7], Rep. Pappas, Chris [D-NH-1], Rep. Bean, Aaron [R-FL-4], Rep. Moulton, Seth [D-MA-6], Rep. Moran, Nathaniel [R-TX-1], Rep. Mullin, Kevin [D-CA-15], Rep. Moolenaar, John R. [R-MI-2] and 31 more

Recent Actions

2025-03-10: Referred to the House Committee on Ways and Means.
2025-03-10: Introduced in House
2025-03-10: Introduced in House

Bill Versions

American Innovation and R&D Competitiveness Act of 2025 — issued 2025-03-10 — PDF (8 pages)